DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Alovudine is an investigational drug.
There have been 4 clinical trials for Alovudine. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2004.
The most common disease conditions in clinical trials are HIV Infections, Immunologic Deficiency Syndromes, and Acquired Immunodeficiency Syndrome. The leading clinical trial sponsors are Lederle Laboratories, Boehringer Ingelheim, and [disabled in preview].
Recent Clinical Trials for Alovudine
|Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure||Boehringer Ingelheim||Phase 2|
|A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)||Lederle Laboratories||N/A|
|An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects||Lederle Laboratories||N/A|